M. de Boer, V.C.G. Tjan-Heijnen
M. de Boer
Trialoffice IKO Radboud University Nijmegen, Medical Centre
PO Box 9101, HP 485 6500 HB Nijmegen
Tel 024 361 68 37
Fax 024 361 90 80
E-mail trialiko@onco.umcn.nl
Data registration and analysis of 3 cohorts: Cohort I: women with node-negative disease who did not receive systemic adjuvant therapy Cohort II: women with isolated tumor cells or micrometastases who did not receive adjuvant therapy Cohort III: women with isolated tumor cells or micrometastases who received adjuvant therapy
The efficiency ratio expressed as incremental costs per disease-free life year gained. Clinical objectives are: The difference in 5-years disease-free and overall survival of patients with isolated tumour cells or micrometastases treated versus not treated with adjuvant systemic therapy (i.e., impact of adjuvant treatment). The difference in 5-years disease-free and overall survival of patients with small nodal metastases versus no metastases, both not treated with adjuvant systemic therapy (i.e., prognostic impact).
Primary endpoint:
Secondary endpoint:
SN before or in 2003 Female
